Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Imprimis Phar (IMMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
ImprimisRx's Dropless® Steroid and Antibiotic Intravitreal Injection Featured in the Prestigious Journal of Cataract and Refractive Surgery

SAN DIEGO , May 30, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.'s (NASDAQ: IMMY) ophthalmology compounding division, ImprimisRx, is pleased to announce the findings from a study published...

IMMY : 2.45 (+6.06%)
ImprimisRx's Dropless® Steroid and Antibiotic Intravitreal Injection Featured in the Prestigious Journal of Cataract and Refractive Surgery

Imprimis Pharmaceuticals, Inc.'s (NASDAQ: IMMY) ophthalmology compounding division, ImprimisRx, is pleased to announce the findings from a study published in the Journal of Cataract and Refractive Surgery...

IMMY : 2.45 (+6.06%)
Imprimis Pharmaceuticals Announces First Quarter 2018 Results

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported financial results for the first quarter 2018.

IMMY : 2.45 (+6.06%)
Surface Pharmaceuticals, Inc. Announces $20 Million Series A Financing from Flying L Partners

SAN DIEGO, and PLEASANTON, Calif. , May 15, 2018 /PRNewswire/ -- Surface Pharmaceuticals, Inc., an affiliated company of Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), today announced it has entered...

IMMY : 2.45 (+6.06%)
Surface Pharmaceuticals, Inc. Announces $20 Million Series A Financing from Flying L Partners

Surface Pharmaceuticals, Inc., an affiliated company of Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), today announced it has entered into a definitive stock purchase agreement with an affiliate of Flying...

IMMY : 2.45 (+6.06%)
Research Report Identifies Albany International, JBG SMITH Properties, Preferred Apartment Communities, National Western Life Group, Phibro Animal Health, and Imprimis Pharmaceuticals with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Albany International Corporation...

APTS : 15.70 (+1.42%)
NWLI : 319.29 (-0.22%)
IMMY : 2.45 (+6.06%)
AIN : 61.40 (+0.08%)
JBGS : 36.86 (-1.60%)
PAHC : 47.35 (-1.25%)
Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt® (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract & Refractive Surgery Medical Meeting

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), and its ophthalmology-focused ImprimisRx division, today announced its participation and related physician presentations at the 2018 American Society of Cataract...

IMMY : 2.45 (+6.06%)
Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it has secured a patent covering the company's innovative MKO (midazolam, ketamine, and ondansetron)...

IMMY : 2.45 (+6.06%)
Analysis: Positioning to Benefit within Enbridge Energy Management, Imprimis Pharmaceuticals, Hibbett Sports, Glacier, Regis, and Fox Factory Holding -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Enbridge Energy Management...

EEQ : 9.54 (+0.74%)
HIBB : 23.00 (-2.54%)
GBCI : 40.86 (-0.56%)
IMMY : 2.45 (+6.06%)
FOXF : 46.50 (+0.87%)
RGS : 17.16 (-2.83%)
Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today reported financial results for the fourth quarter 2017.

IMMY : 2.45 (+6.06%)
Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results

SAN DIEGO , March 8, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today reported financial results for the fourth quarter...

IMMY : 2.45 (+6.06%)
Wired News - Imprimis Pharma Launched New Program for Custom Compounded Ophthalmic Medications

Stock Monitor: Akcea Therapeutics Post Earnings Reporting

IMMY : 2.45 (+6.06%)
AKCA : 26.22 (+1.16%)
Imprimis Pharmaceuticals to Present at 30th Annual ROTH Conference on March 13, 2018

SAN DIEGO , March 7, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that its Chief Executive Officer, Mark...

IMMY : 2.45 (+6.06%)
Imprimis Pharmaceuticals to Present at 30th Annual ROTH Conference on March 13, 2018

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that its Chief Executive Officer, Mark L. Baum, will present an update on the company's business...

IMMY : 2.45 (+6.06%)
Imprimis Pharmaceuticals Announces Program for Custom Compounded Ophthalmic Formulations

SAN DIEGO , March 6, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmic-focused pharmaceutical company, today announced that it has launched a new program to provide...

IMMY : 2.45 (+6.06%)
Imprimis Pharmaceuticals to Host its Fourth Quarter 2017 Financial Report Conference Call and Webcast on March 8, 2018 at 4:30 p.m. EST

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it will release fourth quarter 2017 financial results after the close of trading on Thursday,...

IMMY : 2.45 (+6.06%)
Imprimis Pharmaceuticals to Host its Fourth Quarter 2017 Financial Report Conference Call and Webcast on March 8, 2018 at 4:30 p.m. EST

SAN DIEGO , Feb. 15, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it will release fourth quarter 2017 financial...

IMMY : 2.45 (+6.06%)
Today's Research Reports on Trending Tickers: Corbus Pharmaceuticals and Imprimis Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / January 31, 2018 / U.S. markets fell sharply Tuesday for the second consecutive day. Both the Dow Jones and S&P 500 experienced their largest one day drop of 2018. The Dow...

CRBP : 5.90 (+1.72%)
IMMY : 2.45 (+6.06%)
Imprimis Pharmaceuticals Now Making Available Two Glaucoma Drugs on FDA's Drug Shortage List

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that it is now dispensing preservative-free dorzolamide and a preservative-free dorzolamide/timolol...

IMMY : 2.45 (+6.06%)
Blog Exposure - Imprimis Pharma Received DEA Manufacturer Certificate for 503B Outsourcing Facility

LONDON, UK / ACCESSWIRE / January 26, 2018 / Active-Investors.com has just released a free research report on Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY). If you want access to this report all you need...

IMMY : 2.45 (+6.06%)

Van Meerten Stock Picks

5 Terrific Mid Caps
In this roller coaster market I wanted to find Mid Cap stocks that had consistent price appreciation over the last 6 month period.
EHC -2.19 , FTNT -0.81 , CAKE -2.16 , PLT -0.20 , AEO -0.88
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures closed Friday steady to fractionally mixed, as July was down 1.11% on the week. The USDA reported a private export sale of 131,300 MT of corn to Mexico this morning. The sale was broke down to 30,000 MT for delivery in 2017/18, with the ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar